A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescentsSTYCZYNSKI, J; TALLAMY, B; GEORGE, D et al.Bone marrow transplantation (Basingstoke). 2011, Vol 46, Num 6, pp 790-799, issn 0268-3369, 10 p.Article

Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myelomaSCHMIDT-HIEBER, M; BLAU, I. W; FAUSER, A. A et al.Bone marrow transplantation (Basingstoke). 2007, Vol 39, Num 7, pp 389-396, issn 0268-3369, 8 p.Article

Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trialRUUTU, Tapani; VOLIN, Liisa; BLAU, Igor W et al.Haematologica (Roma). 2011, Vol 96, Num 9, pp 1344-1350, issn 0390-6078, 7 p.Article

Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioningCASPER, J; HOLOWIECKI, J; BLAU, I et al.Bone marrow transplantation (Basingstoke). 2012, Vol 47, Num 9, pp 1171-1177, issn 0268-3369, 7 p.Article